Cryosa Completes $8.25M In Series A-2 Funding For Further Development Of Breakthrough, Minimally Invasive Treatment For Obstructive Sleep Apnea
Cryosa Completes $8.25 Million in Series A-2 Funding for Further Development of Breakthrough, Minimally Invasive Treatment for Obstructive Sleep Apnea MEDICAL ALLEY, Minn., June 25, 2020-- Minnesota medical device startup Cryosa completed its Series A-2 funding, raising $8.25 million to further develop its breakthrough therapies for obstructive sleep apnea (OSA). The round was led by life sciences firm, Santé Ventures, and HOYA Corporation (“HOYA”), with additional institutional and individual investors. This latest funding round will be used to engage in first-in-human clinical trials. The company has completed extensive pre-clinical testing, evaluating safety and efficacy.